Open-Label, Randomised Parallel-Group Study
An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation Therapy.
Prostate Cancer
DRUG: Degarelix|DRUG: Degarelix
To demonstrate efficacy of degarelix in achieving and maintaining testosterone suppression at castrate levels (=0.5 ng/mL) during one year of treatment in prostate cancer patients., 3-month
To evaluate testosterone, PSA, LH, and FSH responses during one year of treatment., 3-month|To evaluate pharmacokinetic response., 3-month|To compare safety and tolerability profiles of different degarelix three-month dosing regimens., 3-month
An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation Therapy.